127 related articles for article (PubMed ID: 37607322)
1. Performance of magnetic resonance imaging-based prostate cancer risk calculators and decision strategies in two large European medical centres.
Davik P; Remmers S; Elschot M; Roobol MJ; Bathen TF; Bertilsson H
BJU Int; 2024 Mar; 133(3):278-288. PubMed ID: 37607322
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Magnetic Resonance Imaging-Based Risk Calculators to Predict Prostate Cancer Risk.
Patel HD; Remmers S; Ellis JL; Li EV; Roobol MJ; Fang AM; Davik P; Rais-Bahrami S; Murphy AB; Ross AE; Gupta GN
JAMA Netw Open; 2024 Mar; 7(3):e241516. PubMed ID: 38451522
[TBL] [Abstract][Full Text] [Related]
3. Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate Cancer.
Deniffel D; Healy GM; Dong X; Ghai S; Salinas-Miranda E; Fleshner N; Hamilton R; Kulkarni G; Toi A; van der Kwast T; Zlotta A; Finelli A; Perlis N; Haider MA
Radiology; 2021 Aug; 300(2):369-379. PubMed ID: 34032510
[TBL] [Abstract][Full Text] [Related]
4. Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD).
Falagario UG; Jambor I; Lantz A; Ettala O; Stabile A; Taimen P; Aronen HJ; Knaapila J; Perez IM; Gandaglia G; Fossati N; Martini A; Cucchiara V; Picker W; Haug E; Ratnani P; Haines K; Lewis S; Sujit N; Selvaggio O; Sanguedolce F; Macarini L; Cormio L; Nordström T; Tewari A; Briganti A; Boström PJ; Carrieri G
Eur Urol Oncol; 2021 Dec; 4(6):971-979. PubMed ID: 32972896
[TBL] [Abstract][Full Text] [Related]
5. Avoiding unnecessary biopsy: the combination of PRIMARY score with prostate-specific antigen density for prostate biopsy decision.
Guo S; Zhang J; Wang Y; Jiao J; Li Z; Cui C; Chen J; Yang W; Ma S; Wu P; Jing Y; Wen W; Kang F; Wang J; Qin W
Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):288-293. PubMed ID: 38160227
[TBL] [Abstract][Full Text] [Related]
6. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C
Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
[TBL] [Abstract][Full Text] [Related]
7. Reducing Biopsies and Magnetic Resonance Imaging Scans During the Diagnostic Pathway of Prostate Cancer: Applying the Rotterdam Prostate Cancer Risk Calculator to the PRECISION Trial Data.
Remmers S; Kasivisvanathan V; Verbeek JFM; Moore CM; Roobol MJ;
Eur Urol Open Sci; 2022 Feb; 36():1-8. PubMed ID: 35098168
[TBL] [Abstract][Full Text] [Related]
8. A prostate biopsy risk calculator based on MRI: development and comparison of the Prospective Loyola University multiparametric MRI (PLUM) and Prostate Biopsy Collaborative Group (PBCG) risk calculators.
Patel HD; Koehne EL; Shea SM; Fang AM; Gerena M; Gorbonos A; Quek ML; Flanigan RC; Goldberg A; Rais-Bahrami S; Gupta GN
BJU Int; 2023 Feb; 131(2):227-235. PubMed ID: 35733400
[TBL] [Abstract][Full Text] [Related]
9. External validation of the Rotterdam prostate cancer risk calculator within a high-risk Dutch clinical cohort.
Hagens MJ; Stelwagen PJ; Veerman H; Rynja SP; Smeenge M; van der Noort V; Roeleveld TA; van Kesteren J; Remmers S; Roobol MJ; van Leeuwen PJ; van der Poel HG
World J Urol; 2023 Jan; 41(1):13-18. PubMed ID: 36245015
[TBL] [Abstract][Full Text] [Related]
10. Using decision curve analysis to benchmark performance of a magnetic resonance imaging-based deep learning model for prostate cancer risk assessment.
Deniffel D; Abraham N; Namdar K; Dong X; Salinas E; Milot L; Khalvati F; Haider MA
Eur Radiol; 2020 Dec; 30(12):6867-6876. PubMed ID: 32591889
[TBL] [Abstract][Full Text] [Related]
11. Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging Scans.
Alberts AR; Schoots IG; Bokhorst LP; van Leenders GJ; Bangma CH; Roobol MJ
Eur Urol; 2016 Jun; 69(6):1129-34. PubMed ID: 26651990
[TBL] [Abstract][Full Text] [Related]
12. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
[TBL] [Abstract][Full Text] [Related]
13. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
[TBL] [Abstract][Full Text] [Related]
14. Elucidating the need for prostate cancer risk calculators in conjunction with mpMRI in initial risk assessment before prostate biopsy at a tertiary prostate cancer center.
Krausewitz P; Büttner T; von Danwitz M; Weiten R; Cox A; Klümper N; Stein J; Luetkens J; Kristiansen G; Ritter M; Ellinger J
BMC Urol; 2024 Mar; 24(1):71. PubMed ID: 38532370
[TBL] [Abstract][Full Text] [Related]
15. Incorporating PHI in decision making: external validation of the Rotterdam risk calculators for detection of prostate cancer.
Rius Bilbao L; Aguirre Larracoechea U; Valladares Gomez C; Remmers S; Mar Medina C;
World J Urol; 2024 Mar; 42(1):141. PubMed ID: 38478041
[TBL] [Abstract][Full Text] [Related]
16. External Validation of the Prostate Biopsy Collaborative Group Risk Calculator and the Rotterdam Prostate Cancer Risk Calculator in a Swedish Population-based Screening Cohort.
Chandra Engel J; Palsdottir T; Ankerst D; Remmers S; Mortezavi A; Chellappa V; Egevad L; Grönberg H; Eklund M; Nordström T
Eur Urol Open Sci; 2022 Jul; 41():1-7. PubMed ID: 35813248
[TBL] [Abstract][Full Text] [Related]
17. The impact of prostate volume estimation on the risk-adapted biopsy decision based on prostate-specific antigen density and magnetic resonance imaging score.
Baudewyns A; Guenzel K; Halinski A; Dariane C; Delavar G; Anract J; Barry Delongchamps N; Jabbour T; Bourgeno HA; Lefebvre Y; Ferriero M; Simone G; Fourcade A; Fournier G; Oderda M; Gontero P; Bernal-Gomez A; Mastrorosa A; Roche JB; Zahr RA; Ploussard G; Fiard G; Rysankova K; Bui AP; Taha F; Windisch O; Benamran D; Vlahopoulos L; Assenmacher G; Roumeguère T; Peltier A; Diamand R
World J Urol; 2024 May; 42(1):322. PubMed ID: 38747982
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Performance of Prostate-specific Antigen Density for Detecting Clinically Significant Prostate Cancer in the Era of Magnetic Resonance Imaging: A Systematic Review and Meta-analysis.
Wang S; Kozarek J; Russell R; Drescher M; Khan A; Kundra V; Barry KH; Naslund M; Siddiqui MM
Eur Urol Oncol; 2024 Apr; 7(2):189-203. PubMed ID: 37640584
[TBL] [Abstract][Full Text] [Related]
19. External Validation of the Rotterdam Prostate Cancer Risk Calculator and Comparison with Stockholm3 for Prostate Cancer Diagnosis in a Swedish Population-based Screening Cohort.
Palsdottir T; Grönberg H; Hilmisson A; Eklund M; Nordström T; Vigneswaran HT
Eur Urol Focus; 2023 May; 9(3):455-462. PubMed ID: 36522257
[TBL] [Abstract][Full Text] [Related]
20. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
